Current prospects for the fluoroquinolones as first-line tuberculosis therapy

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5421-5429

  Takiff, Howard ^a   Guerrero, Elba ^a  

^a Instituto Venezolano de Investigaciones Cientificas Centro de Microbiologia y Biologia Celular   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; SITAFLOXACIN; SPARFLOXACIN;

ADD ON THERAPY; ANTIBIOTIC RESISTANCE; BACILLI; BACTERIAL LOAD; COMMUNITY ACQUIRED PNEUMONIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION RISK; MEDICAL DOCUMENTATION; MULTIDRUG RESISTANT TUBERCULOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SHORT SURVEY; TREATMENT DURATION;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICE; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 81555211930     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00695-11     Document Type: Short Survey

References (96)

1. Adams, K. N., et al. 2011. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145:39-53.
2. Agrawal, D., Z. F. Udwadia, C. Rodriguez, and A. Mehta. 2009. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int. J. Tuberc. Lung Dis. 13:79-83.
3. Ahmad, Z., et al. 2011. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrob. Agents Chemother. 55:1781-1783.
4. Ainsa, J. A., et al. 1998. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J. Bacteriol. 180:5836-5843. (Pubitemid 28514198)
5. Almeida, D., E. Nuermberger, S. Tyagi, W. R. Bishai, and J. Grosset. 2007. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother. 51:4261-4266. (Pubitemid 350209875)
6. Angeby, K. A., et al. 2010. Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. J. Antimicrob. Chemother. 65:946-952.
7. Aubry, A., et al. 2006. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50:104-112. (Pubitemid 43042909)
8. Biomedical Research and Training Institute. Rifaquin. Biomedical Research and Training Institute, Harare, Zimbabwe. http://www.brti.co.zw/index.php? option=com-content&view=article&id=38&Itemid=59.
9. Blumberg, H. M., D. Rimland, D. J. Carroll, P. Terry, and I. K. Wachsmuth. 1991. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J. Infect. Dis. 163:1279-1285.
10. Bouza, E., F. Garcia-Garrote, E. Cercenado, M. Marin, and M. S. Diaz. 1999. Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group. Antimicrob. Agents Chemother. 43:981-982. (Pubitemid 29165775)
11. Bozeman, L., W. Burman, B. Metchock, L. Welch, and M. Weiner. 2005. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin. Infect. Dis. 40:386-391. (Pubitemid 40216506)
12. Burman, W. J., et al. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338. (Pubitemid 44156613)
13. Casal, M., P. Ruiz, and A. Herreras. 2000. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Spanish Study Group of M. tuberculosis Resistance. Int. J. Tuberc. Lung Dis. 4:588-591. (Pubitemid 30409179)
14. Chan, E. D., et al. 2004. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 169:1103-1109. (Pubitemid 38624789)
15. Chen, T. C., P. L. Lu, C. Y. Lin, W. R. Lin, and Y. H. Chen. 2011. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int. J. Infect. Dis. 15:e211-e216.
16. Colijn, C., T. Cohen, A. Ganesh, and M. Murray. 2011. Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS One 6:e18327.
17. Conde, M. B., et al. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189.
18. Cui, Z., J. Wang, J. Lu, X. Huang, and Z. Hu. 2011. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect. Dis. 11:78.
19. Dawe, R. S., S. H. Ibbotson, J. B. Sanderson, E. M. Thomson, and J. Ferguson. 2003. A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity. Br. J. Dermatol. 149:1232-1241. (Pubitemid 38058100)
20. Devasia, R. A., et al. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am. J. Respir. Crit. Care Med. 180:365-370.
21. Dooley, K. E., J. Golub, F. S. Goes, W. G. Merz, and T. R. Sterling. 2002. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin. Infect. Dis. 34:1607-1612. (Pubitemid 34615446)
22. Dorman, S. E., et al. 2009. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 180:273-280.
23. Drlica, K., and X. Zhao. 2007. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44:681-688.
24. East African/British Medical Research Councils Study. 1981. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. Am. Rev. Respir. Dis. 123:165-170.
25. el-Sadr, W. M., et al. 1998. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin. Infect. Dis. 26:1148-1158.
26. Emmerson, A. M., and A. M. Jones. 2003. The quinolones: decades of development and use. J. Antimicrob. Chemother. 51(Suppl. 1):13-20. (Pubitemid 36622100)
27. Gandhi, N. R., et al. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. (Pubitemid 44780738)
28. Gandhi, N. R., et al. 2010. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375:1830-1843.
29. Gillespie, S. H., and O. Billington. 1999. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother. 44:393-395. (Pubitemid 29425693)
30. Ginsburg, A. S., et al. 2003. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin. Infect. Dis. 37:1448-1452. (Pubitemid 37494671)
31. Ginsburg, A. S., et al. 2005. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob. Agents Chemother. 49:3977-3979. (Pubitemid 41233065)
32. Ginsburg, A. S., et al. 2003. The rapid development of fluoroquinolone resistance in M. tuberculosis. N. Engl. J. Med. 349:1977-1978. (Pubitemid 37409723)
33. Golub, J. E., et al. 2005. Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int. J. Tuberc. Lung Dis. 9:392-397. (Pubitemid 40524029)
34. Grimaldo, E. R., et al. 2001. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int. J. Tuberc. Lung Dis. 5:546-550. (Pubitemid 32587285)
35. Gumbo, T., A. Louie, M. R. Deziel, and G. L. Drusano. 2005. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob. Agents Chemother. 49:3178-3181. (Pubitemid 41060557)
36. Helb, D., et al. 2010. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 48:229-237.
37. Hemvani, N., D. S. Chitnis, G. C. Bhatia, and N. Sharma. 2001. Drug resistance among tubercle bacilli from pulmonary tuberculosis cases in central India. Indian J. Med. Sci. 55:382-392.
38. Hu, Y., A. R. Coates, and D. A. Mitchison. 2003. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:653-657. (Pubitemid 36158096)
39. Hu, Y., et al. 2011. Population-based investigation of fluoroquinolones resistant tuberculosis in rural eastern China. Tuberculosis (Edinb.) 91:238-243.
40. Huang, T. S., et al. 2005. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J. Antimicrob. Chemother. 56:1058-1062.
41. Jacobson, K. R., D. B. Tierney, C. Y. Jeon, C. D. Mitnick, and M. B. Murray. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis. 51:6-14.
42. Jeon, C. Y., et al. 2011. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. Int. J. Tuberc. Lung Dis. 15:77-83.
43. Jeon, C. Y., et al. 2008. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin. Infect. Dis. 46:42-49. (Pubitemid 351263558)
44. Johnson, J. L., et al. 2006. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 10:605-612. (Pubitemid 43845020)
45. Kohno, S., H. Koga, M. Kaku, S. Maesaki, and K. Hara. 1992. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 102:1815-1818. (Pubitemid 23001233)
46. Lau, R. W., et al. 2011. Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. Antimicrob. Agents Chemother. 55:608-614.
47. Lesher, G. Y., E. J. Froelich, M. D. Gruett, J. H. Bailey, and R. P. Brundage. 1962. 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J. Med. Pharm. Chem. 91:1063-1065.
48. Liu, C. H., et al. 2011. Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital. Respirology 16:918-925.
49. Livermore, D. M., et al. 2003. Ciprofloxacin-resistant Escherichia coli from bacteraemias in England; increasingly prevalent and mostly from men. J. Antimicrob. Chemother. 52:1040-1042. (Pubitemid 38008432)
50. Long, R., et al. 2009. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin. Infect. Dis. 48:1354-1360.
51. Louw, G. E., et al. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184:269-276.
52. Malik, M., et al. 2011. Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 55:2335-2343.
53. Mandell, L. A., et al. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44(Suppl. 2):S27-S72. (Pubitemid 46290553)
54. Mdluli, K., and Z. Ma. 2007. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect. Disord. Drug Targets 7:159-168. (Pubitemid 47103052)
55. Mitchison, D. A. 1993. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am. Rev. Respir. Dis. 147:1062-1063. (Pubitemid 23093839)
56. Nuermberger, E., et al. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother. 52:1522-1524. (Pubitemid 351522025)
57. Nuermberger, E. L., et al. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169:421-426. (Pubitemid 38134824)
58. Nuermberger, E. L., et al. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170:1131-1134. (Pubitemid 39488628)
59. Parida, S. K., and S. H. Kaufmann. 2010. The quest for biomarkers in tuberculosis. Drug Discov. Today 15:148-157.
60. Park, I. N., et al. 2007. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int. J. Tuberc. Lung Dis. 11:319-324.
61. Park, S. K., et al. 2004. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int. J. Tuberc. Lung Dis. 8:361-368. (Pubitemid 38624874)
62. Pasca, M. R., et al. 2004. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48:3175-3178. (Pubitemid 38989198)
63. Pletz, M. W., et al. 2004. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob. Agents Chemother. 48:780-782. (Pubitemid 38280324)
64. Poissy, J., et al. 2010. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob. Agents Chemother. 54:4765-4771.
65. Pucci, M. J., M. Ackerman, J. A. Thanassi, C. M. Shoen, and M. H. Cynamon. 2010. In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. Antimicrob. Agents Chemother. 54:3478-3480.
66. Renau, T. E., et al. 1996. Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. Antimicrob. Agents Chemother. 40:2363-2368. (Pubitemid 26328047)
67. Riantawan, P., J. Punnotok, R. Chaisuksuwan, and V. Pransujarit. 1998. Resistance of Mycobacterium tuberculosis to antituberculosis drugs in the Central Region of Thailand, 1996. Int. J. Tuberc. Lung Dis. 2:616-620. (Pubitemid 28383852)
68. Rieder, H. L. 1996. Sputum smear conversion during directly observed treatment for tuberculosis. Tuber. Lung Dis. 77:124-129. (Pubitemid 26139144)
69. Rodriguez, J. C., M. Ruiz, M. Lopez, and G. Royo. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20:464-467. (Pubitemid 35379989)
70. Rustomjee, R., et al. 2008. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:128-138. (Pubitemid 351212403)
71. Shandil, R. K., et al. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582. (Pubitemid 46185275)
72. Singapore Tuberculosis Service/British Medical Research Council. 1986. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis. 133:779-783.
73. Soudani, A., et al. 2010. First report of molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates from a Tunisian hospital. Clin. Microbiol. Infect. 16:1454-1457.
74. Strahilevitz, J., G. A. Jacoby, D. C. Hooper, and A. Robicsek. 2009. Plasmid-mediated quinolone resistance: a multifaceted threat. Clin. Microbiol. Rev. 22:664-689.
75. Sullivan, E. A., et al. 1995. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 345:1148-1150.
76. Tahaoglu, K., et al. 2001. The treatment of multidrug-resistant tuberculosis in Turkey. N. Engl. J. Med. 345:170-174. (Pubitemid 32662125)
77. Takiff, H. E., et al. 1996. Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis. Proc. Natl. Acad. Sci. U. S. A. 93:362-366. (Pubitemid 26038159)
78. Takiff, H. E., et al. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780. (Pubitemid 24114017)
79. Tuberculosis Research Center. 2002. Shortening short course chemotherapy: a randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J. Tuberc. 49:27-38.
80. Umubyeyi, A., et al. 2007. Evidence of 'amplifier effect' in pulmonary multidrug-resistant tuberculosis: report of three cases. Int. J. Infect. Dis. 11:508-512. (Pubitemid 47626040)
81. Umubyeyi, A. N., et al. 2007. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J. Antimicrob. Chemother. 59:1031-1033. (Pubitemid 47073381)
82. van den Boogaard, J., H. H. Semvua, M. J. Boeree, R. E. Aarnoutse, and G. S. Kibiki. 2010. Sale of fluoroquinolones in northern Tanzania: a potential threat for fluoroquinolone use in tuberculosis treatment. J. Antimicrob. Chemother. 65:145-147.
83. van den Boogaard, J., et al. 2011. Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania. J. Antimicrob. Chemother. 66:1810-1814.
84. van Ingen, J., et al. 2010. Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 48:2749-2753.
85. Vetting, M. W., et al. 2006. Pentapeptide repeat proteins. Biochemistry 45:1-10. (Pubitemid 43054077)
86. Veziris, N., M. Ibrahim, N. Lounis, K. Andries, and V. Jarlier. 2011. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One 6:e17556.
87. Von Groll, A., et al. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53:4498-4500.
88. Wang, J. Y., et al. 2006. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 61:903-908.
89. Wang, J. Y., et al. 2007. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J. Antimicrob. Chemother. 59:860-865.
90. Wang, J. Y., et al. 2010. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 14:65-71.
91. Williams, K. N., et al. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314-1319.
92. Xu, P., et al. 2009. Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob. Agents Chemother. 53:3170-3172.
93. Yadav, V., and K. Deopujari. 2006. Gatifloxacin and dysglycemia in older adults. N. Engl. J. Med. 354:2725-2726.
94. Yew, W. W., et al. 2003. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 124:1476-1481. (Pubitemid 37290060)
95. Yin, X., and Z. Yu. 2010. Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China. J. Infect. 61:150-154.
96. Yoon, Y. S., et al. 2005. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int. J. Tuberc. Lung Dis. 9:1215-1219. (Pubitemid 41735599)